An open, randomised, comparative, multicentre study of the immunogenicity and safety of M-M-R II [measles mumps and rubella virus vaccine] manufactured with recombinant human albumin (rHA) and VARIVAX [varicella zoster virus vaccine live] when administered concomitantly by intramuscular (IM) route or subcutaneous (SC) route at two separate injection sites in healthy subjects 12 to 18 months of age
Latest Information Update: 09 May 2022
At a glance
- Drugs Measles mumps and rubella virus vaccine (Primary) ; Measles mumps and rubella virus vaccine (Primary) ; Varicella zoster virus vaccine live (Primary) ; Varicella zoster virus vaccine live (Primary)
- Indications Chickenpox; Measles; Mumps; Rubella
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.
- 15 Mar 2007 New trial record.